3 active not recruiting, 2 completed, 2 recruiting, 2 unknown. 5 Phase 1, 4 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Recruiting 2, Active not recruiting 1, Completed 1, Terminated 1 |
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Not yet recruiting 1 |
| Not applicable | 1 | Active not recruiting 1 |
Follow Anophthalmia with pulmonary hypoplasia: new trials by email Literature Review of Anophthalmia with pulmonary hypoplasia trials Research Report on Anophthalmia with pulmonary hypoplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy - Metastatic PDAC, HER2-positive Status | Phase 2 | Active not recruiting | Shanghai Zhongshan Hospital | 45 | 2025-09-30 | 2025-12-05 |
| CHemotherapy And Stool Transplant in PDAC (CHASe-PDAC) Fecal Microbiota Transplantation, PEG3350, Gemcitabine - Unresectable or Metastatic Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | Active not recruiting | John Lenehan | 20 | 2025-01-08 | 2026-10-02 |
| Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies DSB2455 - Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency) | Phase 1 | Recruiting | Duke Street Bio Ltd | 180 | 2024-11-21 | 2026-09-02 |
| Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer surufatinib combined with gemcitabine plus nab-paclitaxel - Pancreatic Cancer, Pancreatic Cancer Non-resectable | Phase 2 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 40 | 2024-06-01 | 2024-04-11 |
| Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures Clinical value of 5 transcriptomic signatures to personalize the therapeutic decision for L1 in PDAC, Biomarkers of tumor signatures (translational studies) - Carcinoma, Pancreatic Ductal, Prognosis | Not applicable | Active not recruiting | Institut Curie | 79 | 2022-12-12 | 2026-10-01 |
| Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan Azirkitug, Budigalimab, Bevacizumab - Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | AbbVie | 694 | 2021-11-01 | 2026-06-23 |
| Influence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic Cancer Pancreatic Ductal Adenocarcinoma, PDAC | Unknown | Ruijin Hospital | 30 | 2021-08-01 | 2022-02-08 | |
| Clinical and Multiomics Study of First-line Chemotherapy for Advanced Pancreatic Cancer Pancreatic Ductal Adenocarcinoma, PDAC | Unknown | Ruijin Hospital | 50 | 2021-01-01 | 2021-12-23 | |
| Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma MEDI4736 in combination with nab-paclitaxel and gemcitabine, MEDI4736 in combination with AZD5069 - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Completed | AstraZeneca | 23 | 2016-03-25 | 2019-08-14 |
| Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma MEDI4736 monotherapy, tremelimumab+MEDI4736 - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | Completed | AstraZeneca | 65 | 2015-11-16 | 2018-08-02 |
| (PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer BTH1704, IMPRIME PGG, Gemcitabine - Pancreatic Cancer | Phase 1 | Terminated | University of Illinois at Chicago | 3 | 2014-08-01 | 2015-05-01 |
| Expanded Access to Mifomelatide for Cachexia in Adults With Advanced PDAC mifomelatide - Pancreatic Ductal Adenocarcinoma (mPDAC), Unresectable Pancreatic Ductal Adenocarcinoma | No longer available | Endevica Bio | 2026-02-18 |
Pancreatic Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Pancreatic Ductal (1) · Esophageal Neoplasms (1) · Fanconi Anemia, Complementation Group D1 (1) · Fanconi Anemia, Complementation Group N (1) · Neoplasm Metastasis (1) · Recurrence (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Digestive System Diseases (5) · Digestive System Neoplasms (5) · Endocrine Gland Neoplasms (5) · Endocrine System Diseases (5) · Neoplasms (5) · Neoplasms by Site (5) · Pancreatic Diseases (5) · Carcinoma (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Adenocarcinoma (1) · Breast Diseases (1) · Breast Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1)
Gemcitabine (4) · 130-nm albumin-bound paclitaxel (3) · Bevacizumab (1) · Drug Therapy (1) · Fecal Microbiota Transplantation (1) · Long Interspersed Nucleotide Elements (1) · N-(2-(2,3-difluoro-6-benzylthio)-6-(3,4-dihydroxybutan-2-yloxy)pyrimidin-4-yl)azetidine-1-sulfonamide (1) · Trastuzumab (1) · budigalimab (1) · durvalumab (1) · epitumomab (1) · polyethylene glycol 3350 (1)
AstraZeneca (2) · Ruijin Hospital (2) · AbbVie (1) · Duke Street Bio Ltd (1) · Endevica Bio (1) · Institut Curie (1) · John Lenehan (1) · Shanghai Zhongshan Hospital (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) · University of Illinois at Chicago (1)
United States (5) · China (4) · Canada (3) · France (2) · South Korea (2) · Spain (2) · Germany (1) · Hungary (1) · Israel (1) · Japan (1) · Netherlands (1) · Poland (1) · Taiwan (1) · United Kingdom (1)
Duowu Zou (2) · Eileen M O'Reilly, M.D (1) · Heshui Wu (1) · Jeff Evans, M.D (1) · Meghan Joly, PhD (1) · Neeta Venepalli, MD (1)